243 related articles for article (PubMed ID: 38673455)
1. Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.
Sanguedolce F; Falagario UG; Zanelli M; Palicelli A; Zizzo M; Busetto GM; Cormio A; Carrieri G; Cormio L
J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673455
[TBL] [Abstract][Full Text] [Related]
2. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
Bedke J; Black PC; Szabados B; Guerrero-Ramos F; Shariat SF; Xylinas E; Brinkmann J; Blake-Haskins JA; Cesari R; Redorta JP
Urol Oncol; 2023 Dec; 41(12):461-475. PubMed ID: 37968169
[TBL] [Abstract][Full Text] [Related]
3. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette-Guérin (BCG) Therapy.
Maas M; Hilsendecker A; Pertoll A; Stühler V; Walz S; Rausch S; Stenzl A; Tsaur I; Hennenlotter J; Aufderklamm S
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611034
[TBL] [Abstract][Full Text] [Related]
5. A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guérin and Immune Checkpoint Inhibitors.
Baek SW; Leem SH
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612609
[TBL] [Abstract][Full Text] [Related]
6. Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin.
Hashizume A; Umemoto S; Yokose T; Nakamura Y; Yoshihara M; Shoji K; Wada S; Miyagi Y; Kishida T; Sasada T
Oncotarget; 2018 Sep; 9(75):34066-34078. PubMed ID: 30344922
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette-Guérin immunotherapy: Current status.
Nowak Ł; Krajewski W; Poterek A; Śliwa A; Zdrojowy R
Arab J Urol; 2020 Jul; 19(1):67-70. PubMed ID: 33763250
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives.
Roviello G; Catalano M; Santi R; Palmieri VE; Vannini G; Galli IC; Buttitta E; Villari D; Rossi V; Nesi G
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503220
[TBL] [Abstract][Full Text] [Related]
10. Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Broughton EI; Gooden KM; Mycock KL; Rajkovic I; Taylor-Stokes G
BMC Urol; 2022 Feb; 22(1):27. PubMed ID: 35219307
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
Roumiguié M; Compérat E; Chaltiel L; Nouhaud FX; Verhoest G; Masson-Lecomte A; Colin P; Audenet F; Houédé N; Larré S; Xylinas E; Brunelle S; Piana-Thomassin J; Cotte J; Pignot G; Neuzillet Y; Rouprêt M
World J Urol; 2021 Nov; 39(11):4055-4065. PubMed ID: 32666225
[TBL] [Abstract][Full Text] [Related]
12. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment.
Civriz AH; Teke K; Akdas EM; Dillioglugil O; Vural C; Yaprak Bayrak B
Urol Oncol; 2023 Dec; 41(12):486.e1-486.e13. PubMed ID: 37690934
[TBL] [Abstract][Full Text] [Related]
14. OncoTherad
Reis IB; Tibo LHS; de Souza BR; Durán N; Fávaro WJ
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5025-5036. PubMed ID: 36322290
[TBL] [Abstract][Full Text] [Related]
15. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.
Kates M; Matoso A; Choi W; Baras AS; Daniels MJ; Lombardo K; Brant A; Mikkilineni N; McConkey DJ; Kamat AM; Svatek RS; Porten SP; Meeks JJ; Lerner SP; Dinney CP; Black PC; McKiernan JM; Anderson C; Drake CG; Bivalacqua TJ
Clin Cancer Res; 2020 Feb; 26(4):882-891. PubMed ID: 31712383
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
17. HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer.
Nam W; Chae HK; Jung Y; Kang H; Park M; Choi A; Park JY; Eom DW; Kim SJ
Front Immunol; 2023; 14():1301510. PubMed ID: 38143745
[TBL] [Abstract][Full Text] [Related]
18. Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC).
Delcourt C; Gemival P; Nouhaud FX; Gobet F; Gillibert A; Ferlicot S; Sabourin JC; Irani J; Pfister C
World J Urol; 2020 Jun; 38(6):1517-1524. PubMed ID: 31486884
[TBL] [Abstract][Full Text] [Related]
19. Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer.
de Jong FC; Rutten VC; Zuiverloon TCM; Theodorescu D
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802033
[TBL] [Abstract][Full Text] [Related]
20. Narrative review: update on immunotherapy and pathological features in patients with bladder cancer.
Aurilio G; Cimadamore A; Lopez-Beltran A; Scarpelli M; Massari F; Verri E; Cheng L; Santoni M; Montironi R
Transl Androl Urol; 2021 Mar; 10(3):1521-1529. PubMed ID: 33850786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
